clinical trial · NCT05748600
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
Areteia Therapeutics·phase3·active not recruiting·n = 600
Eosinophilic AsthmaAsthma; EosinophilicAsthma AttackDexpramipexole DihydrochloridePlacebo
brief summary
The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability of dexpramipexole in participants with eosinophilic asthma.
started
Jan 30, 2023
primary completion
Sep 1, 2025
completion
Dec 1, 2025
last updated
Sep 5, 2025
official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 24 Weeks in Participants With Eosinophilic Asthma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol